In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma.

ABSTRACT:

Introduction

Ependymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent decades, with 10-year survival rates stagnating at just 67% for children aged 0-14 years. Moreover, a proportion of patients who survive treatment often suffer long-term neurological side effects as a result of therapy. It is evident that there is a need for safer, more effective treatments for pediatric EPN patients. There are ten distinct subgroups of EPN, each with their own molecular and prognostic features. To identify and facilitate the testing of new treatments for EPN, in vivo laboratory models representative of the diverse molecular subtypes are required. Here, we describe the establishment of a patie

SUBMITTER: Whitehouse JP 

PROVIDER: S-EPMC10020925 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature